WO2011017201A3 - Antagoniste de dp2 et ses utilisations - Google Patents

Antagoniste de dp2 et ses utilisations Download PDF

Info

Publication number
WO2011017201A3
WO2011017201A3 PCT/US2010/043783 US2010043783W WO2011017201A3 WO 2011017201 A3 WO2011017201 A3 WO 2011017201A3 US 2010043783 W US2010043783 W US 2010043783W WO 2011017201 A3 WO2011017201 A3 WO 2011017201A3
Authority
WO
WIPO (PCT)
Prior art keywords
conditions
antagonist
pharmaceutically acceptable
acceptable salt
diseases
Prior art date
Application number
PCT/US2010/043783
Other languages
English (en)
Other versions
WO2011017201A2 (fr
Inventor
Brian Andrew Stearns
Christopher David King
Jason Edward Brittain
Kevin Ross Holme
Original Assignee
Amira Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amira Pharmaceuticals, Inc. filed Critical Amira Pharmaceuticals, Inc.
Priority to CA2768587A priority Critical patent/CA2768587A1/fr
Priority to MX2012001542A priority patent/MX2012001542A/es
Priority to JP2012523663A priority patent/JP2013501052A/ja
Priority to SG2012007811A priority patent/SG178252A1/en
Priority to EP10806952A priority patent/EP2462110A4/fr
Priority to CN2010800346599A priority patent/CN102596902A/zh
Publication of WO2011017201A2 publication Critical patent/WO2011017201A2/fr
Publication of WO2011017201A3 publication Critical patent/WO2011017201A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C273/00—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C273/02—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of urea, its salts, complexes or addition compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne l'antagoniste de DP2 acide [2'-(3-benzyl-1-éthyl-uréidométhyl)-6-méthoxy-4'-trifluorométhyl-biphényl-3-yl]-acétique, ou l'un de ses sels pharmaceutiquement acceptables. Elle concerne également des procédés de préparation de l'antagoniste de DP2, ou d'un de ses sels pharmaceutiquement acceptables. Elle concerne aussi des compositions pharmaceutiques appropriées à l'administration à un mammifère qui comprennent l'antagoniste de DP2, ou l'un de ses sels pharmaceutiquement acceptables, et des procédés d'utilisation de ces compositions pharmaceutiques pour traiter des maladies ou des conditions respiratoires, des maladies ou des conditions allergiques, des maladies ou des conditions inflammatoires, ainsi que d'autres maladies ou des conditions dépendantes de la prostaglandine D2 ou médiées par la prostaglandine D2.
PCT/US2010/043783 2009-08-05 2010-07-29 Antagoniste de dp2 et ses utilisations WO2011017201A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA2768587A CA2768587A1 (fr) 2009-08-05 2010-07-29 Antagoniste de dp2 et ses utilisations
MX2012001542A MX2012001542A (es) 2009-08-05 2010-07-29 Antagonista dp2 y usos del mismo.
JP2012523663A JP2013501052A (ja) 2009-08-05 2010-07-29 Ｄｐ２アンタゴニストおよびその用途
SG2012007811A SG178252A1 (en) 2009-08-05 2010-07-29 Dp2 antagonist and uses thereof
EP10806952A EP2462110A4 (fr) 2009-08-05 2010-07-29 Antagoniste de dp2 et ses utilisations
CN2010800346599A CN102596902A (zh) 2009-08-05 2010-07-29 Dp2拮抗剂及其用途

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23166009P 2009-08-05 2009-08-05
US61/231,660 2009-08-05

Publications (2)

Publication Number Publication Date
WO2011017201A2 WO2011017201A2 (fr) 2011-02-10
WO2011017201A3 true WO2011017201A3 (fr) 2011-06-16

Family

ID=43503081

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/043783 WO2011017201A2 (fr) 2009-08-05 2010-07-29 Antagoniste de dp2 et ses utilisations

Country Status (12)

Country Link
US (2) US8815917B2 (fr)
EP (1) EP2462110A4 (fr)
JP (1) JP2013501052A (fr)
KR (1) KR20120047273A (fr)
CN (1) CN102596902A (fr)
AR (1) AR079404A1 (fr)
CA (1) CA2768587A1 (fr)
MX (1) MX2012001542A (fr)
SG (2) SG178252A1 (fr)
TW (1) TWI403318B (fr)
UY (1) UY32833A (fr)
WO (1) WO2011017201A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150072963A1 (en) * 2006-06-16 2015-03-12 The Trustees Of The University Of Pennsylvania Compositions and methods for regulating hair growth
CN101952244B (zh) 2008-02-01 2014-11-05 潘米拉制药公司 前列腺素d2受体的n，n-二取代氨基烷基联苯拮抗剂
US20110098352A1 (en) * 2008-02-01 2011-04-28 Amira Pharmaceuticals, Inc. N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
US8497381B2 (en) * 2008-02-25 2013-07-30 Panmira Pharmaceuticals, Llc Antagonists of prostaglandin D2 receptors
GB2463788B (en) * 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
US8378107B2 (en) 2008-10-01 2013-02-19 Panmira Pharmaceuticals, Llc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010042652A2 (fr) 2008-10-08 2010-04-15 Amira Pharmaceuticals, Inc. Antagonistes hétéroalkyl biphényle des récepteurs de la prostaglandine d2
US20100173313A1 (en) * 2009-01-08 2010-07-08 Amira Pharmaceuticals, Inc. Biomarkers of inflammation
US8785393B2 (en) 2009-07-31 2014-07-22 Panmira Pharmaceuticals, Llc Ophthalmic pharmaceutical compositions of DP2 receptor antagonists
CN102596902A (zh) 2009-08-05 2012-07-18 潘米拉制药公司 Dp2拮抗剂及其用途
CA2805452C (fr) 2010-07-05 2018-07-31 Actelion Pharmaceuticals Ltd Derives d'heterocyclyle substitues par un 1-phenyle et leur utilisation en tant que modulateurs des recepteurs de la prostaglandine d2
WO2013088109A1 (fr) 2011-12-16 2013-06-20 Oxagen Limited Combinaison d'un antagoniste de crth2 et d'un inhibiteur de pompe à protons pour le traitement de l'œsophagite à éosinophiles
AU2012356076A1 (en) 2011-12-21 2014-08-14 Actelion Pharmaceuticals Ltd Heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators
JP6127135B2 (ja) 2012-07-05 2017-05-10 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ １−フェニル置換ヘテロシクリル誘導体及びプロスタグランジンｄ２受容体調節剤としてのそれらの使用
ES2690782T3 (es) 2012-10-24 2018-11-22 Nyu Winthrop Hospital Biomarcador no invasivo para identificar sujetos en riesgo de parto prematuro
US20150342906A1 (en) * 2014-05-27 2015-12-03 Yonghua Li Anti-sneeze and nose vestibule care - compositions, methods, and devices
CN111094988A (zh) 2017-09-13 2020-05-01 普罗根尼蒂公司 先兆子痫生物标志物及相关系统和方法
WO2020227570A1 (fr) * 2019-05-08 2020-11-12 Gb001, Inc. Méthodes de traitement de la rhinosinusite chronique à l'aide de pexopiprant
EP4070113A4 (fr) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. Évaluation de la prééclampsie à l'aide de dosages du facteur de croissance placentaire libre et dissocié

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5239084A (en) * 1990-06-29 1993-08-24 Hoffmann-La Roche Inc. Substituted aminoalkyl biphenyl compounds
US20020198251A1 (en) * 1999-08-09 2002-12-26 Bernd Sundermann Substituted 2-dialkylaminoalkylbiphenyl derivatives
WO2005100298A1 (fr) * 2004-04-13 2005-10-27 Merck & Co., Inc. Inhibiteurs de cetp
WO2009099901A1 (fr) * 2008-02-01 2009-08-13 Amira Pharmaceuticals, Inc. Antagonistes aminoalkylbiphényle n, n' disubstitués des récepteurs d2 de la prostaglandine
WO2011014587A2 (fr) * 2009-07-31 2011-02-03 Amira Pharmaceuticals, Inc. Compositions pharmaceutiques ophtalmiques d'antagonsites du récepteur dp2

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827868A (en) * 1991-10-07 1998-10-27 E. R. Squibb & Sons, Inc. Prostaglandin analogs
US5334598A (en) * 1993-03-19 1994-08-02 Merck & Co., Inc. Six-membered ring fused imidazoles substituted with phenoxyphenylacetic acid derivatives
US5565485A (en) * 1993-03-19 1996-10-15 Merck & Co., Inc. Biphenyl compounds useful or endothelin antagonists
US5391566A (en) 1993-07-20 1995-02-21 Merck & Co., Inc. Benzimidazolinones substituted with phenoxyphenylacetic acid derivatives
CO4960662A1 (es) 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
US6617351B1 (en) * 1998-07-31 2003-09-09 Eli Lilly And Company Amide, carbamate, and urea derivatives
AU782404B2 (en) * 1999-04-28 2005-07-28 Sanofi-Aventis Deutschland Gmbh Tri-aryl acid derivatives as PPAR receptor ligands
CA2383135C (fr) * 1999-08-23 2010-11-30 Hiroyuki Hirai Methode d'identification des proprietes d'une substance relativement aux recepteurs de la prostaglandine d2 des humains
US20010047027A1 (en) * 2000-04-12 2001-11-29 Marc Labelle Prostaglandin D2 receptor antagonists
US6878522B2 (en) 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
WO2002094830A2 (fr) * 2001-05-23 2002-11-28 Merck Frosst Canada & Co. Derives de dihydropyrrolo[1,2-a]indole et de tetrahydropyrido[1,2-a]-indole utilises comme antagonistes des recepteurs de prostaglandine d2
US7687664B2 (en) * 2001-06-04 2010-03-30 Eisai R&D Management Co., Ltd. Carboxylic acid derivative, a salt thereof or an ester of them, and medicament comprising it
WO2003006670A2 (fr) 2001-07-09 2003-01-23 Axys Pharmaceuticals, Inc. Derives de l'acide 2-[5-(5-carbamimidoyl-1h-heteroaryl)-6-hydroxybiphenyl-3-yl]-succinique en tant qu'inhibiteurs du facteur viia
JP4484108B2 (ja) * 2002-05-16 2010-06-16 塩野義製薬株式会社 Ｐｇｄ２受容体拮抗作用を有する化合物
ATE327977T1 (de) 2002-10-21 2006-06-15 Warner Lambert Co Tetrahydrochinolin-derivate als crth2 antagonisten
NZ539406A (en) * 2002-10-30 2007-05-31 Merck Frosst Canada Ltd Pyridopyrrolizine and pyridoindolizine derivatives
JP2004182657A (ja) 2002-12-04 2004-07-02 Eisai Co Ltd Ｈｄｌレベル上昇促進剤
EA011087B1 (ru) * 2002-12-20 2008-12-30 Эмджен Инк. Соединения и фармацевтические композиции для лечения воспалительных заболеваний
US7129264B2 (en) 2003-04-16 2006-10-31 Bristol-Myers Squibb Company Biarylmethyl indolines and indoles as antithromboembolic agents
EP1471057B1 (fr) 2003-04-25 2006-01-18 Actimis Pharmaceuticals, Inc. Derivés de l'acid pyrimidinylacétique pour le traitment des maladies associées au CRTH2
US7205329B2 (en) * 2003-05-30 2007-04-17 Microbia, Inc. Modulators of CRTH2 activity
EP1675826A1 (fr) 2003-10-14 2006-07-05 Oxagen Limited Composes presentant une activite antagoniste de crth2
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
JP4922615B2 (ja) 2003-11-26 2012-04-25 武田薬品工業株式会社 受容体機能調節剤
US7019022B2 (en) * 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
GB0409921D0 (en) 2004-05-04 2004-06-09 Novartis Ag Organic compounds
AU2005257999B2 (en) 2004-06-18 2011-12-08 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
DOP2005000123A (es) * 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
GB0415320D0 (en) 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
WO2006018325A1 (fr) 2004-08-17 2006-02-23 Galderma Research & Development, S.N.C. Nouveaux composes bioaromatiques activant les recepteurs de type ppar et leur utilisation dans des compositions cosmetiques ou pharmaceutiques
KR20070089908A (ko) * 2004-09-21 2007-09-04 아더시스 인코포레이티드 Ｃｒｔｈ２ 수용체 길항작용을 나타내는 인돌 아세트산 및이의 용도
EP1814865A4 (fr) * 2004-09-21 2009-09-02 Wyeth Corp Acides benzimidazole acetiques presentant un antagonisme du recepteur crth2 et utilisations associees
GB0422057D0 (en) 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
US20070299122A1 (en) 2004-11-08 2007-12-27 Tobert Jonathan A Method of Treating Pathological Blushing
BRPI0518476A2 (pt) 2004-11-23 2008-11-18 Pfizer Prod Inc compostos e derivados de dibenzil amina
MX2007007830A (es) 2004-12-23 2007-07-25 Glaxo Group Ltd Compuestos de piridina para el tratamiento de enfermedades mediadas por prostaglandina.
NZ556657A (en) 2004-12-27 2010-10-29 Actelion Pharmaceuticals Ltd 2,3,4,9-tetrahydro-1H-carbazole derivatives as CRTH2 receptor antagonists
GB0510584D0 (en) 2005-05-24 2005-06-29 Novartis Ag Organic compounds
GB0518783D0 (en) * 2005-09-14 2005-10-26 Argenta Discovery Ltd Indolizine compounds
JP5114202B2 (ja) 2005-09-27 2013-01-09 塩野義製薬株式会社 Ｐｇｄ２受容体アンタゴニスト活性を有するスルホンアミド誘導体
US20100167986A1 (en) 2005-09-30 2010-07-01 Amjad Ali Cholesteryl Ester Transfer Protein Inhibitors
US8148572B2 (en) 2005-10-06 2012-04-03 Astrazeneca Ab Compounds
GT200600457A (es) 2005-10-13 2007-04-27 Aventis Pharma Inc Sal de fosfato dihidrogeno como antagonistas del receptor de prostaglandina d2
ES2380683T3 (es) 2005-12-15 2012-05-17 Astrazeneca Ab Difenil-éteres, -amidas, -sulfuros y - metanos sustituidos para el tratamiento de la enfermedad respiratoria
ES2614090T3 (es) * 2005-12-29 2017-05-29 Celtaxsys, Inc. Derivados de diamina como inhibidores de leucotrieno A4 hidrolasa
UY30117A1 (es) 2006-01-31 2007-06-29 Tanabe Seiyaku Co Compuesto amina trisustituido
GB0605743D0 (en) 2006-03-22 2006-05-03 Oxagen Ltd Salts with CRTH2 antagonist activity
GB0611695D0 (en) 2006-06-13 2006-07-26 Novartis Ag Organic compounds
PL2051962T3 (pl) 2006-08-07 2012-03-30 Actelion Pharmaceuticals Ltd Pochodne kwasu (3-amino-1,2,3,4-tetrahydro-9h-karbazol-9-ilo)-octowego
KR101397352B1 (ko) 2006-08-21 2014-05-19 어레이 바이오파마 인크. 4-치환된 페녹시페닐아세트산 유도체
WO2008082567A1 (fr) 2006-12-29 2008-07-10 Merck & Co., Inc. Procédé de synthèse d'un inhibiteur de la cetp
US7960567B2 (en) 2007-05-02 2011-06-14 Amgen Inc. Compounds and methods useful for treating asthma and allergic inflammation
JP2010530425A (ja) 2007-06-21 2010-09-09 アクチミス ファーマシューティカルズ インコーポレーテッド Ｃｒｔｈ２アンタゴニストの粒子
UA100983C2 (ru) 2007-07-05 2013-02-25 Астразенека Аб Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
GB0719521D0 (en) 2007-10-05 2007-11-14 Argenta Discovery Ltd Compounds
WO2009061676A2 (fr) * 2007-11-06 2009-05-14 Amira Pharmaceuticals, Inc. Antagonistes de récepteurs pgd2
US20100298368A1 (en) * 2007-11-06 2010-11-25 Amira Pharmaceuticals, Inc. Antagonists of pgd2 receptors
GB0722216D0 (en) 2007-11-13 2007-12-27 Oxagen Ltd Use of crth2 antagonist compounds
GB0722203D0 (en) 2007-11-13 2007-12-19 Oxagen Ltd Use of CRTH2 antagonist compounds
WO2009089192A1 (fr) 2008-01-07 2009-07-16 Ligand Pharmaceuticals Inc. Acides 2-phénylphénoxyacétiques utiles pour traiter des troubles inflammatoires
MX2010007833A (es) * 2008-01-18 2010-08-11 Oxagen Ltd Compuestos que tienen actividad antagonista de crth2.
US20090186293A1 (en) * 2008-01-23 2009-07-23 Bryan Thomas Fannin Dry film protoresist for a micro-fluid ejection head and method therefor
CN101952244B (zh) * 2008-02-01 2014-11-05 潘米拉制药公司 前列腺素d2受体的n，n-二取代氨基烷基联苯拮抗剂
US8242145B2 (en) 2008-02-14 2012-08-14 Panmira Pharmaceuticals, Llc Cyclic diaryl ether compounds as antagonists of prostaglandin D2 receptors
US8497381B2 (en) * 2008-02-25 2013-07-30 Panmira Pharmaceuticals, Llc Antagonists of prostaglandin D2 receptors
EP2268611A2 (fr) 2008-04-02 2011-01-05 Amira Pharmaceuticals, Inc. Antagonistes d aminoalkylphényle de récepteurs de prostaglandine d<sb>2</sb>
US8071807B2 (en) 2008-07-03 2011-12-06 Panmira Pharmaceuticals, Llc Antagonists of prostaglandin D2 receptors
GB2463788B (en) * 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
US8378107B2 (en) 2008-10-01 2013-02-19 Panmira Pharmaceuticals, Llc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010042652A2 (fr) 2008-10-08 2010-04-15 Amira Pharmaceuticals, Inc. Antagonistes hétéroalkyl biphényle des récepteurs de la prostaglandine d2
GB2465062B (en) * 2008-11-06 2011-04-13 Amira Pharmaceuticals Inc Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
WO2010057118A2 (fr) 2008-11-17 2010-05-20 Amira Pharmaceuticals, Inc. Antagonistes hétérocycliques des récepteurs de la prostaglandine d2
US20100173313A1 (en) * 2009-01-08 2010-07-08 Amira Pharmaceuticals, Inc. Biomarkers of inflammation
CN102596193A (zh) 2009-07-31 2012-07-18 潘米拉制药公司 Dp2受体拮抗的皮肤调配物
CN102596902A (zh) 2009-08-05 2012-07-18 潘米拉制药公司 Dp2拮抗剂及其用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5239084A (en) * 1990-06-29 1993-08-24 Hoffmann-La Roche Inc. Substituted aminoalkyl biphenyl compounds
US20020198251A1 (en) * 1999-08-09 2002-12-26 Bernd Sundermann Substituted 2-dialkylaminoalkylbiphenyl derivatives
WO2005100298A1 (fr) * 2004-04-13 2005-10-27 Merck & Co., Inc. Inhibiteurs de cetp
WO2009099901A1 (fr) * 2008-02-01 2009-08-13 Amira Pharmaceuticals, Inc. Antagonistes aminoalkylbiphényle n, n' disubstitués des récepteurs d2 de la prostaglandine
WO2011014587A2 (fr) * 2009-07-31 2011-02-03 Amira Pharmaceuticals, Inc. Compositions pharmaceutiques ophtalmiques d'antagonsites du récepteur dp2

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2462110A4 *

Also Published As

Publication number Publication date
MX2012001542A (es) 2012-06-19
US8815917B2 (en) 2014-08-26
SG10201404662YA (en) 2014-10-30
WO2011017201A2 (fr) 2011-02-10
CA2768587A1 (fr) 2011-02-10
KR20120047273A (ko) 2012-05-11
TW201109015A (en) 2011-03-16
CN102596902A (zh) 2012-07-18
SG178252A1 (en) 2012-03-29
EP2462110A2 (fr) 2012-06-13
AR079404A1 (es) 2012-01-25
US20160136119A1 (en) 2016-05-19
EP2462110A4 (fr) 2013-04-03
JP2013501052A (ja) 2013-01-10
US9572785B2 (en) 2017-02-21
TWI403318B (zh) 2013-08-01
US20110034558A1 (en) 2011-02-10
UY32833A (es) 2011-01-31

Similar Documents

Publication Publication Date Title
WO2011017201A3 (fr) Antagoniste de dp2 et ses utilisations
WO2011106729A3 (fr) Compositions pharmaceutiques de composé spiro-oxindole pour administration topique et leur utilisation en tant qu&#39;agents thérapeutiques.
MX347544B (es) Antagonista de acido lisofostatidico 1 (lpa1) policiclico y usos del mismo.
WO2009066152A3 (fr) Inhibiteurs de ssao/vap-1 de type haloallylamines et leurs utilisations
WO2011159550A3 (fr) Antagoniste du récepteur de l&#39;acide lysophosphatidique et ses utilisations
EP3626253A3 (fr) Formulations stables de linaclotide
WO2012116290A3 (fr) Stéroïdes neuroactifs substitués par 17(20)-z-vinylcyano, promédicaments de ceux-ci et procédés de traitement les utilisant
WO2009033667A3 (fr) Utilisation d&#39;un peptide en tant qu&#39;agent thérapeutique
WO2009033756A3 (fr) Utilisation d&#39;un peptide comme agent thérapeutique
AU2018236805B2 (en) Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives
UA105229C2 (uk) Фармацевтичний склад
MX2011011428A (es) Derivados de acido sulfamoilbenzoico como antagonistas de trpm8.
WO2011014588A3 (fr) Préparations dermiques d&#39;antagonistes du récepteur dp2
WO2012047017A3 (fr) Dérivé 2,3-dihydro-isoindol-1-one et composition le comprenant
WO2010129057A8 (fr) Composés de tétracycline
WO2011025982A3 (fr) Composés tétracycline
WO2012048129A3 (fr) Inhibiteurs de kinase de type polo
WO2012015986A3 (fr) Dérivés substitués de bioxopipéridinyl phtalimide
WO2011123536A8 (fr) Composés polycycliques de tétracycline
WO2011070318A3 (fr) Formulation topique
WO2010107807A3 (fr) Composés destinés au traitement de l&#39;inflammation et de la douleur
EP3228311A3 (fr) Compositions pharmaceutiques et nutritionnelles de l&#39;acide abscisique
WO2012116176A3 (fr) Urées asymétriques et utilisations médicales de celles-ci
WO2011085033A3 (fr) Antagoniste du dp2 et ses utilisations
WO2013057251A3 (fr) Dérivés d&#39;acide hétéroaryl-hydroxamique et leur utilisation pour traiter, améliorer ou prévenir une maladie virale

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080034659.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10806952

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 217589

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2768587

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2012523663

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 12012500198

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2010806952

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: MX/A/2012/001542

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20127005083

Country of ref document: KR

Kind code of ref document: A